EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 12-Oct-2025 03:11 ET (12-Oct-2025 07:11 GMT/UTC)

25-Sep-2025

Low-dose aspirin for individualized cancer prevention in older adults

About The Study: The findings of this analysis suggest that the individualized treatment effect of low-dose aspirin on cancer prevention in older adults varies by participant characteristics. Further study is needed to fully understand the implications of these findings.

Journal: JAMA Oncology

25-Sep-2025

VCU Massey Comprehensive Cancer Center joins leading cancer research centers to reinforce importance of HPV vaccination to prevent cancer

Virginia Commonwealth University
Business Announcement

VCU Massey Comprehensive Cancer Center, along with 61 other National Cancer Institute (NCI)-Designated Cancer Centers, several leading national cancer health organizations and the University of Puerto Rico Comprehensive Cancer Center, have endorsed a joint statement urging the nation’s health care systems, health care providers, parents, caregivers and the public to choose the human papillomavirus (HPV) vaccination for cancer prevention.

25-Sep-2025

Exploring the therapeutic potential of TGF-β inhibitors for liver fibrosis: targeting multiple signaling pathways

Xia & He Publishing Inc.
Peer-Reviewed Publication

Liver fibrosis is a pathological process resulting from various chronic liver injuries that lead to the formation of liver fibrous scars. It can further progress to cirrhosis and even liver cancer. Currently, there are no effective drugs specifically approved for the treatment of liver fibrosis; etiological therapy remains the main treatment strategy. Therefore, it is necessary to develop anti-fibrotic drugs targeting different pathways involved in liver fibrosis. Transforming growth factor-beta (TGF-β) is a key driver of fibrosis, and targeting TGF-β can effectively reduce liver fibrosis. In this review, we discussed the anti-liver fibrosis effects of TGF-β inhibitors through different signaling pathways, including the application of certain active ingredients from Traditional Chinese Medicine.

Journal: Journal of Clinical and Translational Hepatology

25-Sep-2025

From Petri dish to patient care: organoids bring personalized cancer therapy closer

China Anti-Cancer Association
Peer-Reviewed Publication

Tiny, three-dimensional organoid models are reshaping cancer research by recreating the intricate architecture and diversity of human tumors.

Journal: Cancer Biology & Medicine

25-Sep-2025

Nobel Laureate David Baltimore reviews NF-κB research: Mastering cell fate, regulating health and disease

Immunity & Inflammation
Peer-Reviewed Publication

Professor Alexander Hoffmann and Genhong Cheng from University of California, Los Angeles, jointly with Professor David Baltimore from California Institute of Technology, published a review article in the newly launched journal Immunity & Inflammation. This article provides a systematic overview of NF-κB, covering its activation mechanisms, gene regulatory networks, physiological and pathological roles. It also summarizes recent advances in therapeutic strategies targeting NF-κB, offering a critical foundation for deeper understanding the pathway’s functions and mechanisms.

25-Sep-2025

Unfolded Protein Response pathway offers new targets to treat bone weakness in cancer patients

Editorial Office of West China School of Stomatology, Sichuan University
Peer-Reviewed Publication

The unfolded protein response (UPR) is a protective pathway that helps cells manage stress during protein production. Cancer cells exploit this system to survive harsh tumor environments. In bones, they also disrupt the balance of bone-building and bone-resorbing cells, leading to skeletal fragility. Emerging therapies that target the UPR show promise in restoring bone health while selectively killing malignant cells, offering new hope for patients with cancer-associated bone disease.

Journal: Bone Research

25-Sep-2025

A group of genes could anticipate the response to a key breast cancer treatment

Germans Trias i Pujol Research Institute
Peer-Reviewed Publication

A study coordinated from Badalona by IrsiCaixa, the Catalan Institute of Oncology and the Germans Trias i Pujol Research Institute (within the CARE programme) has identified KIMA, a genomic signature that makes it possible to anticipate which patients with HR+/HER2- breast cancer will respond less well to CDK4/6 inhibitors. The finding, published in the journal Clinical and Translational Medicine, may help personalize therapies and design new combinations.

Journal: Clinical and Translational Medicine

25-Sep-2025

UPF researchers design a new experimental screening system to identify peptides with therapeutic potential

Universitat Pompeu Fabra - Barcelona
Peer-Reviewed Publication

An international study led by researchers from the Department of Medicine and Life Sciences (MELIS) of Pompeu Fabra University and Stanford University (California) has designed a system to identify highly selective peptides with high therapeutic potential. The method is based on the use of biologically- and chemically-modified bacteriophages to screen, with a high degree of precision, up to 1 billion peptides simultaneously. This allows identifying those that can successfully distinguish very similar proteins that play a significant role in the development of cancer and diabetes, respectively, and that are currently being treated with non-specific drugs.

Journal: Journal of the American Chemical Society

25-Sep-2025

New study decodes how tumor “stress droplets” fuel resistance—and how to shut them down

Science China Press
Peer-Reviewed Publication

A Science China Life Sciences study reveals that glioblastoma (GBM) hijacks oxygen-deprived conditions by forming nuclear “stress droplets” that activate the enzyme PRMT2, fueling tumor survival independently of the classic HIF pathway. Blocking PRMT2’s phosphorylation with the orphan drug TG02 dismantles these droplets and—when combined with standard chemotherapy temozolomide—restores drug sensitivity, dramatically shrinking tumors and extending survival in resistant mouse models.

Journal: Science China Life Sciences

25-Sep-2025

CU Anschutz researchers discover how lymphatic endothelials cells help the body remember infections

University of Colorado Anschutz Medical Campus
Peer-Reviewed Publication

A study published today in Nature Communications describes how lymphatic endothelial cells assist in generating robust immune memory, offering new insights into how the immune system functions.

Specifically, the researchers found there is a particular genetic program within the lymphatic endothelial cells that enables storage and archival of portions of an immunization or pathogen (antigens) for future use.

The research is among the first to outline that there’s a genetic “transcriptional” program within lymphatic endothelial cells that impact the immune response and could be manipulated.

The study was led by researchers from the University of Colorado Anschutz, with experts in medicine, immunology and microbiology and biochemistry and molecular genetics.

Journal: Nature Communications